When the Immune System Turns Against the Brain
Autoimmune encephalitis reveals the blurred line between neurology and psychiatry
1Hallucinations with immune roots
A Cambridge psychiatrist treated a patient with persistent animal hallucinations unresponsive to antipsychotics. The hallucinations resolved only after plasma exchange therapy, revealing an autoimmune cause. This case highlights how immune-generated antibodies can mimic psychiatric disorders by attacking brain receptors like NMDA, crucial for learning and memory.
2Diagnostic challenges
Autoimmune encephalitis often presents with psychosis symptoms but lacks classic neurological signs like seizures. Diagnosis relies on antibody tests in blood/spinal fluid, MRI inflammation patterns, and rapid symptom progression. The condition accounts for 1-2% of psychosis cases, with untreated cases risking coma or death. Screening protocols vary globally, with Germany and Australia leading routine testing.
3The 2007 breakthrough
A landmark study identified 12 women whose psychosis stemmed from ovarian tumors containing nerve tissue. Their immune systems attacked NMDA receptors shared by tumors and healthy brains. 75% presented with psychosis before developing seizures. This established tumor-associated autoimmune encephalitis as a distinct condition requiring immunotherapy rather than psychiatric treatment.
4Beyond NMDA receptors
Researchers have since discovered dozens of encephalitis-linked antibodies like LGI1, which disrupts neural signaling. Some patients initially diagnosed with dementia fully recover after immunotherapy. Oxford's Belinda Lennox found 5% of screened psychiatric patients carry these antibodies, suggesting many treatable cases are missed in standard psychiatric care.
5SINAPPS2 clinical trial
Ongoing since 2014, this trial tests whether early psychosis patients without neurological symptoms benefit from immunotherapy. Screening 5,000 patients revealed antibodies in 5%, though some may be false positives. The placebo-controlled study tracks 70 participants for 18 months, with results expected in 2027 to guide testing protocols.
6Antibody discovery methods
Researchers incubate patient blood with rodent brain tissue to detect unknown antibodies. At Mayo Clinic, 5-10% of detected antibody activity remains unclassified, suggesting undiscovered autoantibodies. New findings like 2024's CAMKV antibody show cancer patients developing psychosis, expanding known triggers beyond tumors and infections.
7Treatment controversies
Standard therapy includes tumor removal (if present), steroids, plasma exchange, and intravenous immunoglobulins. The University of Utah's ExTINGUISH trial challenges routine monoclonal antibody use, randomly assigning 116 patients to receive either antibodies or placebo after initial treatments to assess necessity.
8Diagnostic overreach risks
While expanding antibody testing could help some, experts warn against overdiagnosing autoimmune encephalitis. Most psychosis requires psychiatric treatment, and false positives could divert resources. The field balances between missing treatable cases and creating unrealistic hopes for those with standard psychiatric conditions.
9Specialized detection patterns
Different antibodies create distinct staining patterns on rodent brain tissue, aiding discovery. NMDAR, LGI1 and Caspr2 antibodies each show unique signatures. This method helps identify new antibodies even when their specific targets are unknown, expanding the diagnostic toolkit for atypical psychiatric presentations.
10Clinical presentation spectrum
Autoimmune encephalitis symptoms range from memory loss to catatonia, often progressing rapidly. Key red flags include poor response to antipsychotics and concurrent neurological signs like mouth-twitching. However, cases like Jones' patient prove some lack classic markers, necessitating clinician suspicion for antibody testing.
11Therapeutic windows
Early immunotherapy dramatically improves outcomes, with some patients recovering fully within weeks. Delayed treatment risks permanent damage as inflammation persists. The SINAPPS2 trial focuses on patients within two years of symptom onset, as later intervention shows diminished returns even when antibodies are present.
12Redrawing medical boundaries
These discoveries challenge the psychiatry-neurology divide, showing how biological mechanisms underlie psychiatric symptoms. As antibody testing becomes more accessible, it may transform care for treatment-resistant psychosis cases, though requires careful implementation to avoid overmedicalizing typical psychiatric conditions.